Products
Oncology
Irinogen®
Irinotecan hydrochloride
Indications
- Metastatic colorectal cancer.
Presentations
- 100 mg x 1 vial
Products
Irinogen®
Irinotecan hydrochloride
Indications
- Metastatic colorectal cancer.
Presentations
- 100 mg x 1 vial
Irinotecan hydrochloride
The material included in this site has been designed exclusively for health professionals for informational purposes, and is intended to provide guidance on the proper use of medicines and to meet their needs for more information.
All texts referring to our products sold under medical prescription correspond to the guidelines approved by the National Administration of Medicines, Food and Medical Technology (ANMAT).
Laboratories Bioprofarma Bagó suggests you always consult a qualified health professional if you have any questions about a particular medical condition.
Bioprofarma Bagó is aware of the importance of the data security and confidentiality. Therefore, at the time you enter information in our server, it is sent to our internal files with the sole purpose of being used to bring products or services of your interest.
Some contents and comments from this site are addressed to health professionals and to the exclusive and personal use of user, with the sole purpose of bringing information associated with our activity. Their reproduction and/or any other use that exceeds the purpose for which it was created, is prohibited, except Bioprofarma Bagó ‘s express permission to reproduce any information therein contained.
Bioprofarma Bagó takes the necessary steps to protect your information from the access by non-authorized third parties or people.
By sending your data through our site, you are expressly giving your consent for the processing of that information and you will be responsible for its truthfulness.
At any time you may have access to your data and/or request the elimination, correction or modification thereof.
In case of references and links to any third parties’ sites, Bioprofarma Bagó will not be responsible for their contents. Each organization or provider shall be responsible for their corresponding sites.